Skip to main content.

Award Extension & Closeout


Period of Performance and Closeout Expectations
Period of performance means the time during which the department may incur new obligations to carry out the work authorized under the award. It is the period between the approved start and end dates or expiration date of the award.

Unless the Federal awarding agency or pass-through entity authorizes an extension, a non-Federal entity must liquidate all obligations incurred under the Federal award not later than 90 calendar days after the end date of the period of performance as specified in the terms and conditions of the Federal award (Uniform Guidance 200.343 - Closeout).

Items not invoiced for and received during the award period of performance are considered unallowable by an auditor, though the PI may consider it to be beneficial to the project and a reasonable expense at the time the order was placed. To avoid audit finding of this nature, orders for items needed for the project should be placed well in advance (60-90 days) of the project expiration date to ensure invoicing and delivery prior to that expiration date.

eRA Commons User Guide
As of January 1, 2017, a Final Research Performance Progress Report (Final RPPR) is required for any grant that has ended and any grant that is not to be extended through award of a new competitive segment. The report is due within 120 days of the end of the project period. This report should be prepared in accordance with instructions provided by the awarding component. See NIH Implementation of Final Research Performance Progress Reports (Final RPPR) (Guide Notice NOT-OD-17-022).

Effective February 9, 2017, if the recipient organization has submitted a renewal application on or before the date by which a Final Research Performance Progress Report (Final-RPPR) would be required for the current competitive segment, then submission of an "Interim RPPR" via eRA Commons is now required. The Interim RPPR (IRPPR) will be used for the submission of a Competing Renewal application (Type 2). See NIH Implementation of the Interim RPPR while a Renewal Application is Under Consideration (Guide Notice NOT-OD-17-037).

The format of the Interim RPPR and the Final RPPR will be the same as the current Annual RPPR, making it easier for recipients to navigate.

Differences between Interim/Final RPPR and the Annual RPPR are few:

  • In the Interim/Final RPPR, only Section D.1 is required in the Participants section
  • Sections F: Changes and Section H: Budget are not part of the Interim/Final RPPR
  • Section I: Outcomes is new. Section I is required for both the Interim/Final RPPR

Note about Interim RPPR and Final RPPR
The Interim RPPR (IRPPR) is used when you are submitting a Competing Renewal application (Type 2). If you opt NOT to apply for a Competing Renewal, complete the Final RPPR as you normally would within 120 days of the project end date. If you are going to complete a Competing Renewal application (or have already submitted such an application), you will submit an Interim RPPR. This must be submitted within 120 days of the project end date.

If you are awarded the renewal, the Interim RPPR will be treated as your Annual RPPR and no other progress reporting will be needed for that segment of the study. If the application is NOT awarded, then the Interim RPPR will be accepted as the Final RPPR.

NIH Presentation on Interim and Final Research Performance Progress Reports
Additional information about Research Performance Progress Report (RPPR)

For the Final RPPR, SPA will:

  • Confirm personnel effort & completion of ECC Certification
  • Confirm Publication Compliance
  • Confirm inventions with the KUCTC Office
  • Submit the FRPPR via the eRA Commons; and
  • Submit the FFR (Final Financial Report) via the Payment Management System (PMS).

Closeout Reports from other Federal or Non-Federal sponsors may be required. Please be sure to review the terms & conditions, notice of award and/or other sponsor policies & procedures for additional information. Please forward to a copy of any final reports submitted to the sponsor.

All financial reports must be approved by SPA prior to submission to the sponsor. Please contact SPA Post Award.

Please visit the myKUMC intranet (login required) to find this information: Transfer Grant from KUMCRI.

Research Administration

University of Kansas Medical Center
Research Administration
Mailstop 1039
3901 Rainbow Boulevard
Kansas City, KS 66160
Office Location: Support Services Building, Suite 120
Phone: 913-588-1261
Fax: 866-255-2129